We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01245530
Recruitment Status : Completed
First Posted : November 22, 2010
Last Update Posted : June 13, 2011
Information provided by:
Whanin Pharmaceutical Company

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of two fixed dose (1200mg/day, 1600mg/day) of INM-176 (a drug of treating dementia) comparing with donepezil for treatment for patients with Alzheimer type dementia.

Condition or disease Intervention/treatment Phase
Alzheimer Type Dementia Drug: Aricept Drug: INM-176 Phase 3

Detailed Description:
Probable Alzheimer type dementia compare INM-176 1200~1600mg/day with Donepezil 5~10mg/day of safety and efficacy to randomization, multicenter, double-blind, double-dummy, parallel Phase III clinical study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 280 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Probable Alzheimer Type Dementia Compare INM-176 1200~1600mg/Day With Donepezil 5~10mg/Day of Safety and Efficacy to Randomization, Multicenter, Double-blind, Double-dummy, Parallel Phase III Clinical Study
Study Start Date : June 2008
Actual Primary Completion Date : February 2011
Actual Study Completion Date : March 2011

Arm Intervention/treatment
Active Comparator: Aricept
Intervention: Drug: Aricept
Drug: Aricept
Aricept Comparator Intervention: Drug: Aricept 5~10 mg orally every day for 24weeks
Other Name: Donepezil HCl

Experimental: INM-176
Intervention: Drug: INM-176
Drug: INM-176
INM-176: Experimental Intervention: Drug:INM-176 600~1200 mg orally every day for 24weeks
Other Name: KR-WAP-026

Primary Outcome Measures :
  1. Change in cognition as assessed by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) total score [ Time Frame: up to 24 weeks ]

Secondary Outcome Measures :
  1. Change from baseline to endpoint in Mini-Mental State Examination (MMSE) [ Time Frame: up to 24 weeks ]
  2. Change from baseline to endpoint in Clinical Dementia Rating [ Time Frame: up to 24 weeks ]
  3. Change from baseline to endpoint in Global Deterioration Scale(GDS) [ Time Frame: up to 24 weeks ]
  4. Change from baseline to endpoint in Korean Activity of Living(K-IADL) [ Time Frame: up to 24 weeks ]
  5. Change from baseline to endpoint in Korean Neuropsychiatric Inventory (NPI) [ Time Frame: up to 24 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female, age range : 50 ~ 80 years old
  2. Informed consent signed and dated by patient or legal representative
  3. Subjects diagnosed with Alzheimer's disease according to DSM-IV criteria
  4. Subjects diagnosed with probable Alzheimer's disease according to the National Institute of Neurological and Communicative Disorders and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria
  5. MMSE score 10 to 26
  6. CDR(Clinical Dementia Rating) score 1~2 or GDS(Global Deterioration Scale) 3~5 stage
  7. Subjects who didn't take any medication for AchEI (donepezil, memantine, galantamin, etc) before treating or can stop medication at least 4 weeks more prior to screening visit
  8. Subjects menopause women or her/his spouse consent with contraception during the study period and 90 days after end of study

Exclusion Criteria:

  1. Subjects with psychiatric disorders other than Alzheimer's disease, such as schizophrenia, depression, bipolar disorder, etc
  2. Subjects diagnosed or accompanied with Dementia due to other Neurodegenerative disorders (AIDS, syphilis, creutzfeldt-jacob disease, Picks Disease, Huntingtons Disease, Parkinsons disease related dementia)
  3. Subjects diagnosed with vascular dementia
  4. Subjects diagnosed with stroke within last 3 months prior to screening visit
  5. Subjects who have medical history of significant hepatic disease in screening visit (2 ULN≤ALT, AST)
  6. Subjects who have medical history of significant renal disease in screening visit (1.5mg/dl≤Serum creatinine)
  7. Subjects who have difficult with regulating blood glucose level with anti-diabetes drug (8.0%<HbA1c)
  8. Subjects who have medical history of myocardial infarction or arrhythmia
  9. Subjects who take warfarin with Atrial fibrillation
  10. Pregnant or nursing women
  11. Subjects who p0articipated in other clinical trail within last 3 months
  12. Subjects who have hypersensitivity to AchEl (acetylcholinesterase inhibitor)
  13. Subjects who have unstable clinical laboratory result in screening visit
  14. Subjects doubted the pulmonary disease on the chest X-ray in screening visit
  15. Subjects considered unsuitable to participate in clinical trail by investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01245530

Layout table for location information
Korea, Republic of
Whanin Pharm.Co.,Ltd.
Seoul, Moonjung, Korea, Republic of, 138-200
Sponsors and Collaborators
Whanin Pharmaceutical Company
Layout table for investigator information
Principal Investigator: SangYoon Kim, MD Seoul National University Bundang Hospital
Layout table for additonal information
Responsible Party: Heesook Nam, Whanin Pharmaceutical Company
ClinicalTrials.gov Identifier: NCT01245530    
Other Study ID Numbers: INM-176
First Posted: November 22, 2010    Key Record Dates
Last Update Posted: June 13, 2011
Last Verified: June 2011
Keywords provided by Whanin Pharmaceutical Company:
Alzheimer disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Neurodegenerative Diseases
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents